联合吸入沙美特罗替卡松和噻托溴铵治疗重度慢性阻塞性肺疾病缓解期的疗效观察

Salmeterol/Fluticasone Combined with Tiotropium in Treatment of Stable Moderate and Severe COPD Patients

目的:观察联合吸入沙美特罗替卡松和噻托溴铵治疗重度慢性阻塞性肺疾病缓解期的疗效。方法:将60例确诊为重度COPD缓解期的患者随机分为沙美特罗替卡松组、噻托溴铵组及沙美特罗替卡松联合噻托溴铵组,分别给予相对应的药物治疗6个月。记录三组治疗前后肺功能、血气分析及不良反应。结果:三组COPD患者经治疗后肺功能均有改善,而沙美特罗替卡松和噻托溴铵联合吸入组比单用沙美特罗替卡松或噻托溴铵肺功能改善更显著(P<0.05),且无严重不良反应。结论:联合吸入沙美特罗替卡松和噻托溴铵治疗重度慢性阻塞性肺疾病缓解期疗效显著,无严重不良反应。

Objective：To observe the therapeutic effects of salmeterol/fluticasone combined with tiotropium in the treatment of stable moderate and severe COPD. Methods：Sixty patients of stable moderate and severe COPD were randomly divided into three groups： salmeterol/fluticasone group,tiotropium group and combination group. The salmeterol/fluticasone group received the therapy of salmeterol/fluticasone only, the tiotropium group received the therapy of tiotropium only and the combination group received the therapy of tiotropium and salmeterol/flutieasone. All patients had received the treatment for 6 months. Lung function and arterial blood gas analysis results before and after treatment and adverse effects of three groups were recorded. Results：After therapy, lung function and arterial blood gas analysis results of all patients were improved. Compared with the salmeterol/fluticasone group and tiotropium group, arterial blood gas analysis results, FEV1/FVC and FEV1 of the combination group improved significantly （P 〈 0. 05 ）. No serious adverse effects occurred during the treatment. Conclusions：The combination therapy with salmeterol/fluticasone and tiotropium of stable moderate and severe COPD patients has remarkable curative effect without serious adverse effects.